iTeos Therapeutics (NASDAQ:ITOS) Cut to Hold at Leerink Partnrs
Leerink Partnrs downgraded shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a strong-buy rating to a hold rating in a report published on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for iTeos Therapeutics’ Q4 2025 earnings at ($0.38) EPS and FY2029 earnings at ($1.78) EPS. Several other research firms also recently weighed in […]
Leerink Partnrs downgraded shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a strong-buy rating to a hold rating in a report published on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for iTeos Therapeutics’ Q4 2025 earnings at ($0.38) EPS and FY2029 earnings at ($1.78) EPS. Several other research firms also recently weighed in […]
